Study S002523

A Phase II Clinical Study to Compare the Efficacy and Safety of Once-Weekly GZR102 Injection and Bi-weekly GZR18 Injection in Type 2 Diabetes Mellitus With Inadequate Glycemic Control on GLP-1 Receptor Agonists, With or Without Oral Antidiabetic Drugs

ClinicalTrials.gov record

Registration

Registration: NCT07055386
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 90
Start: 2025-08-07
Primary completion: 2026-06-28
Lead sponsor: Gan & Lee Pharmaceuticals.
Conditions: Type 2 Diabetes Mellitus (T2DM)
Interventions: DRUG:GZR102; DRUG:GZR18
Results posted: FALSE

Registered primary outcomes

efficiency endpoint [Week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.